

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
19 September 2024 (19.09.2024)



(10) International Publication Number  
**WO 2024/188999 A1**

(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 31/4035 (2006.01)  
C07D 487/10 (2006.01)

(21) International Application Number:

PCT/EP2024/056495

(22) International Filing Date:

12 March 2024 (12.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23161547.7 13 March 2023 (13.03.2023) EP

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85  
Södertälje (SE).

(72) Inventor: **CORNER, Philip Anthony**; AstraZeneca UK  
Limited, 1 Francis Crick Avenue, Cambridge Biomedical  
Campus, Cambridge Cambridgeshire CB2 0AA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-  
TY**; Association 813, Eastbrook House, Shaftesbury Road,  
CAMBRIDGE Cambridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a  
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))  
— in black and white; the international application as filed  
contained color or greyscale and is available for download  
from PATENTSCOPE

(54) Title: CRYSTALLINE FORM



(I)

(57) Abstract: The present specification relates to a crystalline form of (3S)-2-[(5-amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl]-1'-but-2-ynyl-6-fluoro-spiro[isoindoline-3,3'-pyrrolidine]-1,2'-dione, and to compositions and uses thereof.

WO 2024/188999 A1